A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients
Not yet recruiting · NCT07722767 · Registry updated 2026-07-23Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Phase 1b Study of CLN-049 in Combination With Azacitidine and Venetoclax in AML Patients | Hemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myeloid leukemia, neoplasm | Not yet recruiting | Phase 1 | 2026-07-23 | NCT07722767 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Cullinan Therapeutics Inc. | 10 |
3 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| City of Hope | Duarte | United States | 238 |
| MD Anderson | Houston | United States | 56 |
| New York University Langone Health | New York | United States | 18 |